Senores Pharmaceuticals Current Share Price | Senores Pharmaceuticals Stock Screener
SENORES
Pharmaceuticals
Senores Pharmaceuticals Current Stock Price Today
Live Share Price NSE
₹1537.50
▼
-8.20 (-0.53%)
Live Share Price BSE
₹1538.00
▼
-8.35 (-0.54%)
As of August 18, 2026, the live Senores Pharmaceuticals share price (NSE: SENORES) is ₹1,537.50 on NSE and ₹1,538.00 on BSE, down 0.53% from the previous close, with shares trading between ₹1,525.50 and ₹1,562.90 in today's trading session, and a 52-week range of ₹672.75–₹1,545.70.
Analyse Senores Pharmaceuticals stock price data download and track historical price performance.
Use the Senores Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Senores Pharmaceuticals Market Cap
₹7,080.74 Cr.
SENORES P/E Ratio (TTM)
54.43
Senores Pharmaceuticals P/B Ratio
7.63
EPS (TTM)
₹26.39
Dividend Yield
-
Debt to Equity
0.58
SENORES 52 Week High
₹1545.70
Senores Pharmaceuticals 52 Week Low
₹672.75
Operating Margin
30.00%
Profit Margin
16.94%
SENORES Revenue (TTM)
₹183.00
EBITDA
₹57.00
Net Income
₹31.00
Total Assets
₹1,604.00
Total Equity
₹934.00
Senores Pharmaceuticals Current Share Price Chart
Track the current Senores Pharmaceuticals share price and stock price with an interactive chart. Analyse SENORES price trends, trading volume, historical performance, and volatility across different timeframes — the complete Senores Pharmaceuticals stock quote in one place.
Senores Pharmaceuticals Company Profile - Fundamental Screener
Screen Senores Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for SENORES shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE0RB801010
Senores Pharmaceuticals Balance Sheet Screener
Screen SENORES balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 1,604 | 1,227 | 622 | 131 | 59 |
| Current Assets | 812 | 722 | 251 | 51 | 27 |
| Fixed Assets | 726 | 301 | 235 | 27 | 7 |
| Liabilities | |||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 215 | 174 | 143 | 34 | 13 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 934 | 812 | 232 | 46 | 37 |
| Share Capital | 46 | 46 | 31 | 10 | 9 |
| Reserves & Surplus | 888 | 740 | 174 | 36 | 28 |
Senores Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Senores Pharmaceuticals income statement and profit fundamentals.
Analyze SENORES quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Senores Pharmaceuticals share price evaluation.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 183 | 193 | 178 | 159 | 134 | 126 | 108 | 100 | 80 | 104 | 80 |
| Expenses | 126 | 128 | 121 | 112 | 104 | 95 | 77 | 77 | 59 | 80 | 64 |
| EBITDA | 57 | 65 | 58 | 47 | 30 | 31 | 31 | 23 | 21 | 24 | 16 |
| Operating Profit % | 30.00% | 27.00% | 29.00% | 27.00% | 20.00% | 17.00% | 25.00% | 21.00% | 26.00% | 22.00% | 19.00% |
| Depreciation | 10 | 9 | 8 | 8 | 6 | 5 | 4 | 4 | 4 | 4 | 3 |
| Interest | 7 | 9 | 5 | 6 | 5 | 5 | 6 | 5 | 5 | 3 | 3 |
| Profit Before Tax | 40 | 47 | 45 | 41 | 27 | 21 | 21 | 16 | 14 | 18 | 10 |
| Tax | 9 | 11 | 11 | 11 | 5 | 3 | 4 | 3 | 3 | 3 | 3 |
| Net Profit | 31 | 37 | 34 | 30 | 21 | 18 | 16 | 13 | 11 | 14 | 7 |
| EPS | 6.61 | 7.96 | 7.29 | 6.54 | 4.60 | 3.81 | 5.04 | 3.92 | 3.39 | 8.03 | 4.01 |
Senores Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen SENORES cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March |
|---|---|---|---|---|
| Operating Activities | -46 | -26 | -1 | -10 |
| Investing Activities | -430 | -54 | -48 | -24 |
| Financing Activities | 573 | 87 | 46 | 37 |
| Net Cash Flow | 98 | 8 | -3 | 2 |
Senores Pharmaceuticals Shareholding Pattern Screener
See Senores Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Senores Pharmaceuticals promoter holding and ownership changes for SENORES on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Jul | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 45.82% | 45.82% | 45.77% | 45.78% | 45.80% | 45.80% | 66.66% | 45.76% |
| FII Holding | 3.64% | 6.62% | 4.17% | 3.67% | 4.28% | 3.35% | 0.00% | 5.51% |
| DII Holding | 9.61% | 9.77% | 9.65% | 9.51% | 8.61% | 9.31% | 0.00% | 18.61% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 31.64% | 29.25% | 31.43% | 31.44% | 31.09% | 31.94% | 0.00% | 27.88% |
| Other Holding | 9.30% | 8.55% | 8.97% | 9.60% | 10.22% | 9.59% | 33.34% | 2.23% |
| Shareholder Count | 34,126 | 36,498 | 37,653 | 36,389 | 34,917 | 34,401 | 177 | 43,707 |
Senores Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Senores Pharmaceuticals dividend history with payout and yield data.
View Senores Pharmaceuticals dividend details including ex-dates and amounts for SENORES stock.
Senores Pharmaceuticals Stock Index Membership
See which indices include Senores Pharmaceuticals stock.
Check SENORES index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE INDEX BSE HC
BSE INDEX BSEIPO
BSE INDEX SMLCAP
NIFTY IPO
Senores Pharmaceuticals Market Events Screener - Corporate Actions
Get Senores Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Senores Pharmaceuticals stock events that may affect SENORES share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-07-27 | 2026-07-27 | Quarterly Result Announcement | NA | 0.02% |
| 2026-05-14 | 2026-05-14 | Quarterly Result Announcement | NA | 4.79% |
| 2026-01-31 | 2026-01-31 | Extraordinary General Meeting | NA | -6.84% |
| 2026-01-20 | 2026-01-20 | Quarterly Result Announcement | NA | -0.71% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -2.12% |
| 2025-09-18 | 2025-09-18 | Annual General Meeting | NA | -3.98% |
| 2025-07-23 | 2025-07-23 | Quarterly Result Announcement | NA | -0.19% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | 11.84% |
| 2025-01-23 | 2025-01-23 | Quarterly Result Announcement | NA | -6.09% |
Senores Pharmaceuticals Competitors Screener - Peer Comparison
Screen SENORES competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 449,899 | 37.28 | 61,674 | 12.69% | 11,565 | 33.60 |
| Divis Laboratories | 227,984 | 77.10 | 11,067 | 13.95% | 2,568 | 74.07 |
| Torrent Pharmaceuticals | 189,081 | 86.36 | 13,886 | 20.34% | 2,138 | 54.91 |
| Cipla | 115,611 | 34.42 | 29,045 | 2.24% | 3,870 | 44.38 |
| Zydus Life Science | 112,255 | 24.59 | 27,658 | 17.64% | 5,026 | 46.32 |
| Lupin | 102,054 | 18.61 | 29,039 | 26.75% | 5,356 | 32.17 |
| Dr Reddys Laboratories | 98,391 | 31.25 | 35,059 | 3.90% | 4,158 | 43.27 |
| Mankind Pharma | 98,293 | 47.94 | 14,636 | 14.85% | 1,938 | 38.61 |
| Laurus Labs | 97,930 | 89.15 | 6,868 | 22.01% | 890 | 64.93 |
| Aurobindo Pharma | 94,650 | 25.43 | 34,145 | 5.56% | 3,503 | 59.26 |
Senores Pharmaceuticals Company Announcements - News Screener
Screen SENORES latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-08-14 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-14 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-04 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-08-04 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-08-03 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-07-28 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-27 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-07-27 | Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Raised Through Preferential Issue Of Convertible Equity Warrants For The Quarter Ended On June 30 2026 | - |
| 2026-07-27 | Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended On June 30 2026 | - |
| 2026-07-27 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-07-27 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-07-27 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-07-27 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-07-27 | Financial Results For Quarter Ended June 30 2026 | - |
| 2026-07-27 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-07-21 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-07-21 | Board Meeting Intimation for Considering And Approving The Unaudited Consolidated And Standalone Financial Results Of The Company For The Quarter Ended June 30 2026 And To Transact Other Business Matters | - |
| 2026-07-07 | Submission Of Reconciliation Of Share Capital Audit Report For The Quarter Ended June 30 2026 | - |
| 2026-07-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-03 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |